Laura Perin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Perin has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
- Stefano Da Sacco
GOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics in Urology, Saban Research Institute, Division of Urology, Children’s Hospital Los Angeles (CHLA), Los Angeles, CA 90027, USA
19 shared publications Roger E. De Filippo
GOFARR Laboratory, Children’s Hospital Los Angeles, Division of Urology, Saban Research Institute, Los Angeles, CA 90027, USA
15 shared publicationsAstgik Petrosyan
GOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics in Urology, Saban Research Institute, Division of Urology, Children's Hospital Los Angeles, Los Angeles, California, USA
11 shared publicationsSargis Sedrakyan
GOFARR Laboratory Children's Hospital Los Angeles Division of Urology Saban Research Institute Los Angeles CA 90027 USA
11 shared publicationsRoger De Filippo
GOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics, Division of Urology, Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, USA
7 shared publicationsStefano Da Sacco
The GOFARR Laboratory, The Saban Research Institute, Division of Urology, Children’s Hospital Los Angeles, Los Angeles, CA, United States
7 shared publications
Latest Publications
- Open Access
Physiological Reference Mapping Reveals Context-Dependent Dysregulation of Regenerative Programs in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) involves chronic degeneration and regeneration, causing dystrophic muscle stem cells (MuSCs) to differ from uninjured wild-type tissue. Conventional disease-versus-resting-control comparisons may therefore conflate dysregulation with regeneration. We developed a physiological reference-mapping framework integrating normal regeneration trajectories with replicated dystrophic datasets to estimate disease-associated deviations relative to regenerative state and spatial context. We applied it across single-cell/single-nucleus, bulk, and spatial RNA-sequencing datasets. In a replicated genotype-by-state MuSC dataset comprising wild-type (WT) and dystrophin-deficient mdx mouse samples across four lineage states, with three biological replicates per group, activated mdx MuSCs showed excessive extracellular matrix induction (standardized mdx-WT difference = 1.431; FDR = 3.69 × 10−9) and an attenuated MYC-associated response (−0.731; FDR = 2.57 × 10−4) among five prespecified programs. Spatial decomposition indicated substantial within-niche remodeling beyond altered niche composition. Physiological calibration identified extracellular matrix induction as a normal transient program that becomes excessive in dystrophy and suggested that reduced oxidative phosphorylation transcription relative to resting muscle may represent insufficient suppression relative to normal regeneration. An independent human dystrophinopathy spatial cohort supported increased whole-biopsy extracellular matrix transcription. Physiological reference mapping therefore helps distinguish regenerative adaptation from context-dependent disease dysregulation in DMD.
Open AccessPhysiological Reference Mapping Reveals Context-Dependent Dysregulation of Regenerative Programs in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) involves chronic degeneration and regeneration, causing dystrophic muscle stem cells (MuSCs) to differ from uninjured wild-type tissue. Conventional disease-versus-resting-control comparisons may therefore conflate dysregulation with regeneration. We developed a physiological reference-mapping framework integrating normal regeneration trajectories with replicated dystrophic datasets to estimate disease-associated deviations relative to regenerative state and spatial context. We applied it across single-cell/single-nucleus, bulk, and spatial RNA-sequencing datasets. In a replicated genotype-by-state MuSC dataset comprising wild-type (WT) and dystrophin-deficient mdx mouse samples across four lineage states, with three biological replicates per group, activated mdx MuSCs showed excessive extracellular matrix induction (standardized mdx-WT difference = 1.431; FDR = 3.69 × 10−9) and an attenuated MYC-associated response (−0.731; FDR = 2.57 × 10−4) among five prespecified programs. Spatial decomposition indicated substantial within-niche remodeling beyond altered niche composition. Physiological calibration identified extracellular matrix induction as a normal transient program that becomes excessive in dystrophy and suggested that reduced oxidative phosphorylation transcription relative to resting muscle may represent insufficient suppression relative to normal regeneration. An independent human dystrophinopathy spatial cohort supported increased whole-biopsy extracellular matrix transcription. Physiological reference mapping therefore helps distinguish regenerative adaptation from context-dependent disease dysregulation in DMD.
- Open Access
- 23 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Hypothyroidism impairs skeletal muscle regeneration after injury by altering myogenic and nonmyogenic pathways
Thyroid hormone signaling is an essential regulator of skeletal muscle development, function, and metabolism, yet the specific signaling pathways required for muscle regeneration are not yet defined. We used scRNA-seq and the FUCCI (fluorescent ubiquitination-based cell cycle indicator) reporter mouse model to examine how hypothyroidism impacts repair processes after cardiotoxin-induced injury in mice. During regeneration, and up to 2 months after injury, hypothyroid muscles displayed smaller myofibers and a shift to slower oxidative fiber types. scRNA-seq of tibialis anterior muscle during regeneration revealed that hypothyroidism reduced myogenic-lineage diversity. Cell cycle analysis confirmed delayed cell cycle progression at 5 and 14 days after injury, with skeletal muscle stem cells stalled at the G 1 /S transition, hindering differentiation. Transcriptomic data revealed altered nonmyogenic dynamics, including elevated activated fibro-adipogenic progenitors (FAPs) early in repair and persistent proinflammatory macrophages. Integrative regulon and ligand-receptor analysis further demonstrated that triiodothyronine acted through dual modes: a direct transcriptional control of myogenic cell cycle and oxidative programs and an indirect paracrine remodeling mediated by FAP and immune signaling networks. This study identified what we believe to be novel effects of hypothyroidism on myogenic heterogeneity and impaired tissue repair, offering insights into muscle-wasting mechanisms relevant to hypothyroidism-associated myopathy and sarcopenia.
- 23 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Open AccessHypothyroidism impairs skeletal muscle regeneration after injury by altering myogenic and nonmyogenic pathways
Thyroid hormone signaling is an essential regulator of skeletal muscle development, function, and metabolism, yet the specific signaling pathways required for muscle regeneration are not yet defined. We used scRNA-seq and the FUCCI (fluorescent ubiquitination-based cell cycle indicator) reporter mouse model to examine how hypothyroidism impacts repair processes after cardiotoxin-induced injury in mice. During regeneration, and up to 2 months after injury, hypothyroid muscles displayed smaller myofibers and a shift to slower oxidative fiber types. scRNA-seq of tibialis anterior muscle during regeneration revealed that hypothyroidism reduced myogenic-lineage diversity. Cell cycle analysis confirmed delayed cell cycle progression at 5 and 14 days after injury, with skeletal muscle stem cells stalled at the G 1 /S transition, hindering differentiation. Transcriptomic data revealed altered nonmyogenic dynamics, including elevated activated fibro-adipogenic progenitors (FAPs) early in repair and persistent proinflammatory macrophages. Integrative regulon and ligand-receptor analysis further demonstrated that triiodothyronine acted through dual modes: a direct transcriptional control of myogenic cell cycle and oxidative programs and an indirect paracrine remodeling mediated by FAP and immune signaling networks. This study identified what we believe to be novel effects of hypothyroidism on myogenic heterogeneity and impaired tissue repair, offering insights into muscle-wasting mechanisms relevant to hypothyroidism-associated myopathy and sarcopenia.
- Open Access
- 23 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Extracellular vesicle miR-93-5p cargo regulates glomerular endothelial cell damage in Alport syndrome
Modulation of miRNA expression in glomerular cells is associated with renal disease. Here, we investigated the role of miR-93-5p in mitigating glomerular damage in Alport syndrome and whether the disease-modifying activity of extracellular vesicles from human amniotic fluid stem cells (hAFSC-EVs) is mediated by their miR-93-5p cargo. We identified downregulation of miR-93-5p specifically in glomerular endothelial cells in Alport syndrome along disease progression. Silencing of miR-93-5p in hAFSC-EVs changed the transcriptomic and proteomic profile, regulating EV disease-modifying activity. Compared with naive hAFSC-EVs, silenced hAFSC-EVs did not rescue glomerular endothelial function in vitro and did not restore kidney function in vivo. We established that hAFSC-EVs regulate VEGFR1 and VEGFR2 signaling by miR-93-5p cargo transfer, highlighting that miR-93-5p can restore glomerular endothelial cell biology. Spatial transcriptomics analysis of hAFSC-EV–injected kidneys showed that these EVs can reverse pathways altered during disease progression by stimulating proregenerative processes, specifically in the glomerulus, by regulating miR-93-5p targets. Alteration of glomerular endothelial cell transcriptomics and miR-93-5p targets was also confirmed in biopsies of patients with Alport syndrome using spatial molecular imaging. We demonstrated the critical role of miR-93-5p in glomerular endothelial cells and the capability of hAFSC-EVs to regulate miR-93-5p and its targets in Alport syndrome.
- 23 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Open AccessExtracellular vesicle miR-93-5p cargo regulates glomerular endothelial cell damage in Alport syndrome
Modulation of miRNA expression in glomerular cells is associated with renal disease. Here, we investigated the role of miR-93-5p in mitigating glomerular damage in Alport syndrome and whether the disease-modifying activity of extracellular vesicles from human amniotic fluid stem cells (hAFSC-EVs) is mediated by their miR-93-5p cargo. We identified downregulation of miR-93-5p specifically in glomerular endothelial cells in Alport syndrome along disease progression. Silencing of miR-93-5p in hAFSC-EVs changed the transcriptomic and proteomic profile, regulating EV disease-modifying activity. Compared with naive hAFSC-EVs, silenced hAFSC-EVs did not rescue glomerular endothelial function in vitro and did not restore kidney function in vivo. We established that hAFSC-EVs regulate VEGFR1 and VEGFR2 signaling by miR-93-5p cargo transfer, highlighting that miR-93-5p can restore glomerular endothelial cell biology. Spatial transcriptomics analysis of hAFSC-EV–injected kidneys showed that these EVs can reverse pathways altered during disease progression by stimulating proregenerative processes, specifically in the glomerulus, by regulating miR-93-5p targets. Alteration of glomerular endothelial cell transcriptomics and miR-93-5p targets was also confirmed in biopsies of patients with Alport syndrome using spatial molecular imaging. We demonstrated the critical role of miR-93-5p in glomerular endothelial cells and the capability of hAFSC-EVs to regulate miR-93-5p and its targets in Alport syndrome.
- 14 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (832) , eadw2206
Endothelial cell–released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome
Idiopathic nephrotic syndrome (INS) is a podocyte disease triggered by immune-derived factors. Endothelial activation occurs in this context, but whether the activated endothelium contributes to podocyte injury is unknown. We tested the hypothesis that CD93, a protein primarily expressed in the endothelium, is a contributory factor of podocyte injury. We studied 460 patients with INS and 150 with other podocytopathies. CD93 was analyzed in kidney tissue, urine, and serum samples. We tested the efficacy of CD93 blockade in vitro and in vivo and investigated the relationship between soluble CD93 and clinical outcomes in human INS. CD93 was highly expressed by glomerular endothelial cells (GEnCs) in human INS, and INS sera stimulated cultured human GEnCs to release CD93. Mechanistically, soluble CD93 mediated podocyte activation via β1 integrin/FAK signaling in cultured human podocytes. CD93 blockade mitigated the activation of cultured human podocytes and albumin permeability in human GEnC-podocyte cocultures as well as albuminuria, glomerulosclerosis, and podocyte loss in two models of nephrotic syndrome: podocyte-specific transforming growth factor–β1 signaling ( PodTgfbr1 ) mice and adriamycin-treated mice. Cd93 knockout mice showed less proteinuria and glomerulosclerosis, compared with controls, after adriamycin injection. In patients with INS, soluble CD93 was high in urine in ~90% and 50% of patients in relapse and remission, respectively. High urinary CD93 was associated with faster decline in kidney function and slower response to immunosuppression. Soluble and glomerular CD93 was also elevated in other podocytopathies. We conclude that soluble CD93 contributes to podocyte injury.
- 14 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (832) , eadw2206
Endothelial cell–released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome
Idiopathic nephrotic syndrome (INS) is a podocyte disease triggered by immune-derived factors. Endothelial activation occurs in this context, but whether the activated endothelium contributes to podocyte injury is unknown. We tested the hypothesis that CD93, a protein primarily expressed in the endothelium, is a contributory factor of podocyte injury. We studied 460 patients with INS and 150 with other podocytopathies. CD93 was analyzed in kidney tissue, urine, and serum samples. We tested the efficacy of CD93 blockade in vitro and in vivo and investigated the relationship between soluble CD93 and clinical outcomes in human INS. CD93 was highly expressed by glomerular endothelial cells (GEnCs) in human INS, and INS sera stimulated cultured human GEnCs to release CD93. Mechanistically, soluble CD93 mediated podocyte activation via β1 integrin/FAK signaling in cultured human podocytes. CD93 blockade mitigated the activation of cultured human podocytes and albumin permeability in human GEnC-podocyte cocultures as well as albuminuria, glomerulosclerosis, and podocyte loss in two models of nephrotic syndrome: podocyte-specific transforming growth factor–β1 signaling ( PodTgfbr1 ) mice and adriamycin-treated mice. Cd93 knockout mice showed less proteinuria and glomerulosclerosis, compared with controls, after adriamycin injection. In patients with INS, soluble CD93 was high in urine in ~90% and 50% of patients in relapse and remission, respectively. High urinary CD93 was associated with faster decline in kidney function and slower response to immunosuppression. Soluble and glomerular CD93 was also elevated in other podocytopathies. We conclude that soluble CD93 contributes to podocyte injury.
- Open Access
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 13, 1749288
Editorial: Stem cells and kidney regeneration: transforming renal medicine
Understand the mechanisms regulating development and disease progression (2)(3)(4). The contributions assembled in this Research Topic reflect the innovation in this space, offering not only therapeutic hope but also new conceptual frameworks for understanding kidney regeneration and disease mechanisms.The emerging idea that the adult kidney may regain regenerative abilities through transcriptional reprogramming is at the base of the study by Pode-Shakked and colleagues. This study explores the reactivation of developmental genes, SIX2 and OSR1, in adult human kidney epithelial cells, demonstrating how developmental biology can be exploited to induce regenerative processes. By reintroducing SIX2, the Authors observed an enhancement in cellular self-renewal and in the ability to form organized tubular structures in vivo, suggesting that adult kidney cells retain plasticity that can be unlocked when cells are stimulated by specific signaling. Yet, the study also serves as a cautionary tale: OSR1, while activating developmental programs, was associated with malignant transformation in a subset of cells, mimicking features of Wilms tumor. This duality of regeneration versus tumorigenesis underscores the fragile balance that must be maintained when manipulating developmental pathways in adult tissues.Complementary, the work by Gyarmati et al. shifts attention to an often-overlooked player in renal physiology: the macula densa. Traditionally viewed as a sensor of tubular sodium concentration, the macula densa is revealed here as a potent source of regenerative signals. The identification of CCN1, an angiogenic and anti-fibrotic factor, positions the macula densa as a novel therapeutic target and a potential cellular source for regenerative interventions. This discovery frames the macula densa cells as a regenerative niche, underscoring their relevance in the field by leveraging the kidney's intrinsic repair mechanisms rather than relying solely on exogenous cell replacement.While cellular therapies hold great promise, the challenges of immunogenicity, scalability, and safety have prompted interest in cell-free alternatives. The review by Ceccotti and colleagues offers a comprehensive and timely synthesis of the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs). These vesicles, enriched with specific regenerative cargo, have demonstrated the ability to modulate inflammation, fibrosis, and oxidative stress. The EV-based approach is particularly attractive due to its versatility and safety profile. By combining the therapeutic effects of stem cells into a nano-sized, acellular format, MSC-EVs circumvent many of the regulatory hurdles associated with live cell therapies. The review not only consolidates the preclinical evidence but also points to early clinical data suggesting feasibility and safety, paving the way for broader EV translational efforts for kidney disease. Looking ahead, several hurdles will need to be addressed. First, the field must continue to refine strategies that balance efficacy with safety, particularly when manipulating potent developmental genes. Second, there is a need for more physiologically relevant models that can bridge the gap between preclinical promise and clinical application. Third, standardization of cell sources, EV isolation protocols, and delivery methods will be critical for regulatory approval and widespread adoption. Finally, the integration of personalized medicine approaches, including patient-derived cells and organoids, will be essential to tailor therapies to individual disease profiles and genetic backgrounds.In sum, the contributions in this Research Topic, while presenting recent discoveries related to kidney regeneration, redefine its possibilities. These studies offer us a glimpse into a future where kidney failure will be a treatable condition, where regeneration replaces replacement, and where the kidney's own biology becomes its best medicine.
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 13, 1749288
Open AccessEditorial: Stem cells and kidney regeneration: transforming renal medicine
Understand the mechanisms regulating development and disease progression (2)(3)(4). The contributions assembled in this Research Topic reflect the innovation in this space, offering not only therapeutic hope but also new conceptual frameworks for understanding kidney regeneration and disease mechanisms.The emerging idea that the adult kidney may regain regenerative abilities through transcriptional reprogramming is at the base of the study by Pode-Shakked and colleagues. This study explores the reactivation of developmental genes, SIX2 and OSR1, in adult human kidney epithelial cells, demonstrating how developmental biology can be exploited to induce regenerative processes. By reintroducing SIX2, the Authors observed an enhancement in cellular self-renewal and in the ability to form organized tubular structures in vivo, suggesting that adult kidney cells retain plasticity that can be unlocked when cells are stimulated by specific signaling. Yet, the study also serves as a cautionary tale: OSR1, while activating developmental programs, was associated with malignant transformation in a subset of cells, mimicking features of Wilms tumor. This duality of regeneration versus tumorigenesis underscores the fragile balance that must be maintained when manipulating developmental pathways in adult tissues.Complementary, the work by Gyarmati et al. shifts attention to an often-overlooked player in renal physiology: the macula densa. Traditionally viewed as a sensor of tubular sodium concentration, the macula densa is revealed here as a potent source of regenerative signals. The identification of CCN1, an angiogenic and anti-fibrotic factor, positions the macula densa as a novel therapeutic target and a potential cellular source for regenerative interventions. This discovery frames the macula densa cells as a regenerative niche, underscoring their relevance in the field by leveraging the kidney's intrinsic repair mechanisms rather than relying solely on exogenous cell replacement.While cellular therapies hold great promise, the challenges of immunogenicity, scalability, and safety have prompted interest in cell-free alternatives. The review by Ceccotti and colleagues offers a comprehensive and timely synthesis of the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs). These vesicles, enriched with specific regenerative cargo, have demonstrated the ability to modulate inflammation, fibrosis, and oxidative stress. The EV-based approach is particularly attractive due to its versatility and safety profile. By combining the therapeutic effects of stem cells into a nano-sized, acellular format, MSC-EVs circumvent many of the regulatory hurdles associated with live cell therapies. The review not only consolidates the preclinical evidence but also points to early clinical data suggesting feasibility and safety, paving the way for broader EV translational efforts for kidney disease. Looking ahead, several hurdles will need to be addressed. First, the field must continue to refine strategies that balance efficacy with safety, particularly when manipulating potent developmental genes. Second, there is a need for more physiologically relevant models that can bridge the gap between preclinical promise and clinical application. Third, standardization of cell sources, EV isolation protocols, and delivery methods will be critical for regulatory approval and widespread adoption. Finally, the integration of personalized medicine approaches, including patient-derived cells and organoids, will be essential to tailor therapies to individual disease profiles and genetic backgrounds.In sum, the contributions in this Research Topic, while presenting recent discoveries related to kidney regeneration, redefine its possibilities. These studies offer us a glimpse into a future where kidney failure will be a treatable condition, where regeneration replaces replacement, and where the kidney's own biology becomes its best medicine.
- 30 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (771) , eadl5514
A kidney-specific fasting-mimicking diet induces podocyte reprogramming and restores renal function in glomerulopathy
Cycles of a fasting-mimicking diet (FMD) promote regeneration and reduce damage in the pancreases, blood, guts, and nervous systems of mice, but their effect on kidney disease is unknown. In addition, a FMD has not been tested in rats. Here, we show that cycles of a newly developed low-salt FMD (LS-FMD) restored normal proteinuria and nephron structure and function in rats with puromycin-induced nephrosis compared with that in animals with renal damage that did not receive the dietary intervention. LS-FMD induced modulation of a nephrogenic gene program, resembling renal developmental processes in multiple kidney structures. LS-FMD also activated podocyte-lineage reprogramming pathways and promoted a quiescent state in mature podocytes in the rat kidney damage model. In a pilot clinical study in patients with chronic kidney disease, FMD cycles of 5 days each month for 3 months promoted renoprotection, including reduction of proteinuria and improved endothelial function, compared with that in patients who did not receive the FMD cycles. These results show that FMD cycles, which promote the reprogramming of multiple renal cell types and lead to glomerular damage reversal in rats, should be tested further for the treatment of progressive kidney diseases.
- 30 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (771) , eadl5514
A kidney-specific fasting-mimicking diet induces podocyte reprogramming and restores renal function in glomerulopathy
Cycles of a fasting-mimicking diet (FMD) promote regeneration and reduce damage in the pancreases, blood, guts, and nervous systems of mice, but their effect on kidney disease is unknown. In addition, a FMD has not been tested in rats. Here, we show that cycles of a newly developed low-salt FMD (LS-FMD) restored normal proteinuria and nephron structure and function in rats with puromycin-induced nephrosis compared with that in animals with renal damage that did not receive the dietary intervention. LS-FMD induced modulation of a nephrogenic gene program, resembling renal developmental processes in multiple kidney structures. LS-FMD also activated podocyte-lineage reprogramming pathways and promoted a quiescent state in mature podocytes in the rat kidney damage model. In a pilot clinical study in patients with chronic kidney disease, FMD cycles of 5 days each month for 3 months promoted renoprotection, including reduction of proteinuria and improved endothelial function, compared with that in patients who did not receive the FMD cycles. These results show that FMD cycles, which promote the reprogramming of multiple renal cell types and lead to glomerular damage reversal in rats, should be tested further for the treatment of progressive kidney diseases.
- Open Access
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
The spatially resolved transcriptome signatures of glomeruli in chronic kidney disease
Here, we used digital spatial profiling (DSP) to describe the glomerular transcriptomic signatures that may characterize the complex molecular mechanisms underlying progressive kidney disease in Alport syndrome, focal segmental glomerulosclerosis, and membranous nephropathy. Our results revealed significant transcriptional heterogeneity among diseased glomeruli, and this analysis showed that histologically similar glomeruli manifested different transcriptional profiles. Using glomerular pathology scores to establish an axis of progression, we identified molecular pathways with progressively decreased expression in response to increasing pathology scores, including signal recognition particle–dependent cotranslational protein targeting to membrane and selenocysteine synthesis pathways. We also identified a distinct signature of upregulated and downregulated genes common to all the diseases investigated when compared with nondiseased tissue from nephrectomies. These analyses using DSP at the single-glomerulus level could help to increase insight into the pathophysiology of kidney disease and possibly the identification of biomarkers of disease progression in glomerulopathies.
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Open AccessThe spatially resolved transcriptome signatures of glomeruli in chronic kidney disease
Here, we used digital spatial profiling (DSP) to describe the glomerular transcriptomic signatures that may characterize the complex molecular mechanisms underlying progressive kidney disease in Alport syndrome, focal segmental glomerulosclerosis, and membranous nephropathy. Our results revealed significant transcriptional heterogeneity among diseased glomeruli, and this analysis showed that histologically similar glomeruli manifested different transcriptional profiles. Using glomerular pathology scores to establish an axis of progression, we identified molecular pathways with progressively decreased expression in response to increasing pathology scores, including signal recognition particle–dependent cotranslational protein targeting to membrane and selenocysteine synthesis pathways. We also identified a distinct signature of upregulated and downregulated genes common to all the diseases investigated when compared with nondiseased tissue from nephrectomies. These analyses using DSP at the single-glomerulus level could help to increase insight into the pathophysiology of kidney disease and possibly the identification of biomarkers of disease progression in glomerulopathies.
- Open Access
- 16 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (4)
C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy
The deposition of antipodocyte autoantibodies in the glomerular subepithelial space induces primary membranous nephropathy (MN), the leading cause of nephrotic syndrome worldwide. Taking advantage of the glomerulus-on-a-chip system, we modeled human primary MN induced by anti-PLA2R antibodies. Here we show that exposure of primary human podocytes expressing PLA2R to MN serum results in IgG deposition and complement activation on their surface, leading to loss of the chip permselectivity to albumin. C3a receptor (C3aR) antagonists as well as C3AR gene silencing in podocytes reduced oxidative stress induced by MN serum and prevented albumin leakage. In contrast, inhibition of the formation of the membrane-attack-complex (MAC), previously thought to play a major role in MN pathogenesis, did not affect permselectivity to albumin. In addition, treatment with a C3aR antagonist effectively prevented proteinuria in a mouse model of MN, substantiating the chip findings. In conclusion, using a combination of pathophysiologically relevant in vitro and in vivo models, we established that C3a/C3aR signaling plays a critical role in complement-mediated MN pathogenesis, indicating an alternative therapeutic target for MN.
- 16 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (4)
Open AccessC3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy
The deposition of antipodocyte autoantibodies in the glomerular subepithelial space induces primary membranous nephropathy (MN), the leading cause of nephrotic syndrome worldwide. Taking advantage of the glomerulus-on-a-chip system, we modeled human primary MN induced by anti-PLA2R antibodies. Here we show that exposure of primary human podocytes expressing PLA2R to MN serum results in IgG deposition and complement activation on their surface, leading to loss of the chip permselectivity to albumin. C3a receptor (C3aR) antagonists as well as C3AR gene silencing in podocytes reduced oxidative stress induced by MN serum and prevented albumin leakage. In contrast, inhibition of the formation of the membrane-attack-complex (MAC), previously thought to play a major role in MN pathogenesis, did not affect permselectivity to albumin. In addition, treatment with a C3aR antagonist effectively prevented proteinuria in a mouse model of MN, substantiating the chip findings. In conclusion, using a combination of pathophysiologically relevant in vitro and in vivo models, we established that C3a/C3aR signaling plays a critical role in complement-mediated MN pathogenesis, indicating an alternative therapeutic target for MN.
- Open Access
- 14 July 2023
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 278 (6) , e1313-e1326
Mitochondria Transplantation Mitigates Damage in an In Vitro Model of Renal Tubular Injury and in an Ex Vivo Model of DCD Renal Transplantation
Objectives: To test whether mitochondrial transplantation (MITO) mitigates damage in two models of acute kidney injury (AKI). Summary Background Data: MITO is a process where exogenous isolated mitochondria are taken up by cells. As virtually any morbid clinical condition is characterized by mitochondrial distress, MITO may find a role as a treatment modality in numerous clinical scenarios including AKI. Methods: For the in vitro experiments, human proximal tubular cells were damaged and then treated with mitochondria or placebo. For the ex vivo experiments, we developed a non-survival ex vivo porcine model mimicking the donation after cardiac death (DCD) renal transplantation scenario. One kidney was treated with mitochondria, while the mate organ received placebo, before being perfused at room temperature for 24 hours. Perfusate samples were collected at different time points and analyzed with Raman spectroscopy. Biopsies taken at baseline and 24 hours were analyzed with standard pathology, immunohistochemistry and RNA sequencing analysis. Results: In vitro, cells treated with MITO showed higher proliferative capacity and ATP production, preservation of physiological polarization of the organelles and lower toxicity and reactive oxygen species production. Ex vivo, kidneys treated with MITO shed fewer molecular species, indicating stability. In these kidneys, pathology showed less damage while RNAseq analysis showed modulation of genes and pathways most consistent with mitochondrial biogenesis and energy metabolism and downregulation of genes involved in neutrophil recruitment, including IL1A, CXCL8, and PIK3R1. Conclusions: MITO mitigates AKI both in vitro and ex vivo.
- 14 July 2023
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 278 (6) , e1313-e1326
Open AccessMitochondria Transplantation Mitigates Damage in an In Vitro Model of Renal Tubular Injury and in an Ex Vivo Model of DCD Renal Transplantation
Objectives: To test whether mitochondrial transplantation (MITO) mitigates damage in two models of acute kidney injury (AKI). Summary Background Data: MITO is a process where exogenous isolated mitochondria are taken up by cells. As virtually any morbid clinical condition is characterized by mitochondrial distress, MITO may find a role as a treatment modality in numerous clinical scenarios including AKI. Methods: For the in vitro experiments, human proximal tubular cells were damaged and then treated with mitochondria or placebo. For the ex vivo experiments, we developed a non-survival ex vivo porcine model mimicking the donation after cardiac death (DCD) renal transplantation scenario. One kidney was treated with mitochondria, while the mate organ received placebo, before being perfused at room temperature for 24 hours. Perfusate samples were collected at different time points and analyzed with Raman spectroscopy. Biopsies taken at baseline and 24 hours were analyzed with standard pathology, immunohistochemistry and RNA sequencing analysis. Results: In vitro, cells treated with MITO showed higher proliferative capacity and ATP production, preservation of physiological polarization of the organelles and lower toxicity and reactive oxygen species production. Ex vivo, kidneys treated with MITO shed fewer molecular species, indicating stability. In these kidneys, pathology showed less damage while RNAseq analysis showed modulation of genes and pathways most consistent with mitochondrial biogenesis and energy metabolism and downregulation of genes involved in neutrophil recruitment, including IL1A, CXCL8, and PIK3R1. Conclusions: MITO mitigates AKI both in vitro and ex vivo.
- Open Access
- 28 April 2023
- Published by Wiley in Advanced Science
- Vol. 10 (20) , e2206787
Identification and Characterization of the Wilms Tumor Cancer Stem Cell
A nephrogenic progenitor cell (NP) with cancer stem cell characteristics driving Wilms tumor (WT) using spatial transcriptomics, bulk and single cell RNA sequencing, and complementary in vitro and transplantation experiments is identified and characterized. NP from WT samples with NP from the developing human kidney is compared. Cells expressing SIX2 and CITED1 fulfill cancer stem cell criteria by reliably recapitulating WT in transplantation studies. It is shown that self‐renewal versus differentiation in SIX2+CITED1+ cells is regulated by the interplay between integrins ITGβ1 and ITGβ4. The spatial transcriptomic analysis defines gene expression maps of SIX2+CITED1+ cells in WT samples and identifies the interactive gene networks involved in WT development. These studies define SIX2+CITED1+ cells as the nephrogenic‐like cancer stem cells of WT and points to the renal developmental transcriptome changes as a possible driver in regulating WT formation and progression.
- 28 April 2023
- Published by Wiley in Advanced Science
- Vol. 10 (20) , e2206787
Open AccessIdentification and Characterization of the Wilms Tumor Cancer Stem Cell
A nephrogenic progenitor cell (NP) with cancer stem cell characteristics driving Wilms tumor (WT) using spatial transcriptomics, bulk and single cell RNA sequencing, and complementary in vitro and transplantation experiments is identified and characterized. NP from WT samples with NP from the developing human kidney is compared. Cells expressing SIX2 and CITED1 fulfill cancer stem cell criteria by reliably recapitulating WT in transplantation studies. It is shown that self‐renewal versus differentiation in SIX2+CITED1+ cells is regulated by the interplay between integrins ITGβ1 and ITGβ4. The spatial transcriptomic analysis defines gene expression maps of SIX2+CITED1+ cells in WT samples and identifies the interactive gene networks involved in WT development. These studies define SIX2+CITED1+ cells as the nephrogenic‐like cancer stem cells of WT and points to the renal developmental transcriptome changes as a possible driver in regulating WT formation and progression.